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Abstract
Epigenetic changes through altered DNA methylation have been implicated in critical aspects of tumor progression, and 
have been extensively studied in a variety of cancer types. In contrast, our current knowledge of the aberrant genomic 
DNA methylation in tumor-associated fibroblasts (TAFs) or other stromal cells that act as critical coconspirators of tumor 
progression is very scarce. To address this gap of knowledge, we conducted genome-wide DNA methylation profiling on 
lung TAFs and paired control fibroblasts (CFs) from non-small cell lung cancer patients using the HumanMethylation450 
microarray. We found widespread DNA hypomethylation concomitant with focal gain of DNA methylation in TAFs 
compared to CFs. The aberrant DNA methylation landscape of TAFs had a global impact on gene expression and a 
selective impact on the TGF-β pathway. The latter included promoter hypermethylation-associated SMAD3 silencing, 
which was associated with hyperresponsiveness to exogenous TGF-β1 in terms of contractility and extracellular matrix 
deposition. In turn, activation of CFs with exogenous TGF-β1 partially mimicked the epigenetic alterations observed in 
TAFs, suggesting that TGF-β1 may be necessary but not sufficient to elicit such alterations. Moreover, integrated pathway-
enrichment analyses of the DNA methylation alterations revealed that a fraction of TAFs may be bone marrow-derived 
fibrocytes. Finally, survival analyses using DNA methylation and gene expression datasets identified aberrant DNA 
methylation on the EDARADD promoter sequence as a prognostic factor in non-small cell lung cancer patients. Our 
findings shed light on the unique origin and molecular alterations underlying the aberrant phenotype of lung TAFs, and 
identify a stromal biomarker with potential clinical relevance.
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Introduction
Lung cancer is the leading cause of cancer-related deaths world-
wide. Non-small cell lung cancer (NSCLC) accounts for ~85% of 
all lung cancers, and includes two major histologic subtypes: 
adenocarcinoma (ADC) and squamous cell carcinoma (SCC) (1). 
Although both NSCLC subtypes are epithelial in origin, there is 
growing awareness that tumor progression in NSCLC and other 
solid tumors is driven by the aberrant coevolution of carci-
noma cells and surrounding stromal cells (2,3). Among the lat-
ter, tumor-associated fibroblasts (TAFs) are the most abundant 
cell type, and have been implicated in all major steps of tumor 
progression including cancer cell growth, invasion, chemor-
resistance and stemness (4). Importantly, there is growing evi-
dence that TAFs exhibit enhanced tumor-promoting effects 
compared to fibroblasts from unaffected tissue (5). Thus, a better 
understanding of the aberrant molecular differences between 
normal fibroblasts and TAFs is needed to unveil their tumor-
promoting effects.
Most of our knowledge of the tumor-promoting effects of 
lung TAFs has been obtained from cell culture assays and animal 
models (5–7). These studies have consistently reported that the 
aberrant phenotype of TAFs is maintained for some passages in 
culture in the absence of continuous interaction with carcinoma 
cells. Similar observations have been reported in other cancer 
types, strongly supporting that critical phenotypic alterations 
in TAFs are maintained through epigenetic mechanisms (3,8,9).
DNA methylation is the most well-studied epigenetic 
alteration in cancer, owing in part to recent developments in 
genome-wide DNA methylation profiling techniques (10). DNA 
methylation involves the covalent modification of the cytosine 
in a cytosine-phosphate-guanine (CpG) island within genomic 
DNA, which is catalyzed by DNA methyltransferases. Previous 
studies have shown that global loss of DNA methylation (hypo-
methylation) and promoter hypermethylation-associated gene 
inactivation are common epigenetic hallmarks of cancer cells 
(11,12). In NSCLC, several DNA methylation alterations have 
been described in association with the neoplastic transforma-
tion, and some of them have been pointed as potential biomark-
ers with clinical relevance for diagnosis, prognosis and response 
to therapy (10,13). However, former DNA methylation studies in 
lung cancer examining either whole tumor tissue samples or 
cancer cell lines have omitted the epigenetic alterations specifi-
cally affecting TAFs or other stromal components (13,14). Indeed, 
our current knowledge of genome-wide epigenetic alterations 
within the tumor stroma in human cancer is very scarce, and 
has been only explored in breast and gastric cancers (8,15).
Here, we present a detailed analysis of the DNA methylation 
patterns of low-passage primary cultures of TAFs from 12 surgi-
cal patients diagnosed with early stage NSCLC, and paired con-
trol fibroblasts (CFs) isolated from unaffected lung parenchyma. 
We found widespread DNA hypomethylation concomitant with 
focal gain of DNA methylation in TAFs compared to CFs. These 
epigenetic changes had a global impact on gene expression and, 
remarkably, a selective impact in the promoters of critical tran-
scription factors of the TGF-β pathway, including SMAD3, which 
was associated with an aberrant response to exogenous TGF-β1. 
Pathway enrichment analysis of the aberrant genomic methyla-
tion in TAFs provided new insights on their partial bone marrow 
origin. Moreover, we found that aberrant DNA methylation of 
selected candidates was retrospectively associated with shorter 
survival on NSCLC patients, thereby uncovering DNA methyla-
tion biomarkers with potential clinical value.
Materials and methods
Tissue samples and primary human lung fibroblasts
Lung tissue samples were obtained from a cohort of 20 early stage NSCLC 
surgical patients (10 ADC, 10 SCC) prior to 2013 at the Hospital Clinic de 
Barcelona (HCB, Spain) with the approval of the Ethics Committees of the 
HCB and the Universitat de Barcelona. All patients gave their informed 
consent. Selected patients were male, chemo-naïve, Caucasian, ≥55 years 
old and current smokers with confirmed ADC or SCC diagnosis (further 
clinical characteristics are shown in Supplementary Table 1, available at 
Carcinogenesis Online). Samples from tumor and paired tumor-free lung 
parenchyma were collected. A  fraction of each sample was paraffin-
embedded for histologic analysis, whereas the remaining was used to iso-
late CFs and TAFs by outgrowth of tissue explants as described elsewhere 
(6). In brief, tumor samples were chopped in ~1 mm2 fragments, gently 
distributed into a six-well plate, and incubated in regular culture medium 
containing 10% fetal bovine serum (FBS) and antibiotics for 3–4 weeks, 
changing the medium every 2–3 days. During this time frame, fibroblasts 
outgrew from tissue fragments and proliferated over the well surface. 
Tissue explants were removed and fibroblasts were subcultured by trypsi-
nization before reaching confluence. Fibroblasts were used up to passage 
6. Primary cultures were tested negative for mycoplasma. The mesenchy-
mal origin of the fibroblasts was confirmed by their positive and nega-
tive immunofluorescence staining with vimentin and pan-cytokeratin 
antibodies, respectively. DNA methylation profiling of primary fibroblasts 
was conducted on 12 patients, whereas all other molecular biology and 
microscopy analyses were carried out on randomly selected patients from 
our cohort.
Histology
Immunohistochemical analyses of α-SMA, CD34, CD45 and EDARADD were 
performed on tissues from our cohort (n = 20) using the Bond automated 
immunohistochemistry system (Leica Microsystems). Nuclei were coun-
terstained with hematoxylin. Primary antibodies included anti-α-SMA 
(1A4), anti-CD34 (QBEnd-10), anti-CD45 (2B11+, Dako) and anti-EDARADD 
(ab121581, Abcam). Histological staining were imaged with a bright-field 
microscope (BX43) coupled to a digital camera (DP72) using a ×40 objective 
(Olympus). All image processing henceforth was carried out with Image J 
(16) under the guidance of our pathologist (JR). To assess the presence of 
fibrocyte-like cells in CD34 and CD45 staining, fibroblasts were identified 
within stromal mesenchymal cells according to their elongated spindle-
shaped nuclei, discarding those lining blood vessels (6). EDARADD staining 
in fibroblasts was scored in a semiquantitative manner as described else-
where (6). In brief, EDARADD staining was scored blind by two independ-
ent observers according to three categories (negative, weak and strong) 
(see Supplementary Material, available at Carcinogenesis Online for further 
details).
Cell culture
Primary fibroblasts were maintained in culture medium as reported else-
where (6). Unless otherwise indicated, experiments were conducted on 
tissue culture plastic substrata coated with 0.1 mg/ml collagen-I solu-
tion (Millipore) overnight at 4°C. Fibroblasts were seeded at 8 × 103 cells/
cm2. For methylation array studies, fibroblasts were cultured for 5 days in 
serum-free culture medium (SFM) supplemented with 0.1% FBS. In some 
Abbreviations 
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CpG cytosine-phosphate-guanine 
ECM extracellular matrix 
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experiments, fibroblasts were cultured on collagen-coated polyacrylamide 
gels engineered to exhibit normal (~1 kPa) or tumor-like (~30 kPa) Young´s 
elastic moduli (E) (6) in the presence or absence of 2.5 ng/ml TGF-β1 (R&D 
Systems) for 5 days. For extracellular matrix (ECM) expression analysis, 
cells were cultured on collagen-coated rigid substrata in SFM supple-
mented with 2.5 ng/ml TGF-β1 for 5 days.
Infinium 450K DNA methylation profiling
We used the EZ DNA Methylation Kit (Zymo Research) for bisulfite conver-
sion of 500 ng genomic DNA of CFs and paired TAFs from 12 randomly 
selected patients from of our cohort (clinical characteristics shown in 
Supplementary Table  1, available at Carcinogenesis Online). The corre-
sponding DNA methylation profiles were obtained with the Infinium 450K 
Methylation Array as described previously (17), which quantifies meth-
ylation levels (β-value) of ~450 000 CpGs located both at gene promoter 
and non-promoter regions (10). Raw fluorescence intensity values were 
normalized in Illumina Genome Studio software (V2010.3) using ‘control 
normalization’ without background correction. Normalized intensities 
were used to calculate β-values (GSE68851). All methylation data analysis 
was carried out henceforth with the R Software for Statistical Computing 
(v3.1.1). Data points with insufficient fluorescent intensities (P > 0.01) 
were excluded from the analysis. Likewise, genotyping probes present 
on the chip as well as DNA methylation probes overlapping with known 
single-nucleotide polymorphisms were removed. A  differential meth-
ylation analysis between CFs and TAFs was conducted applying paired 
comparisons via moderated t-statistics provided by the linear models 
implemented in limma Bioconductor package (18) to identify statistically 
significant differential DNA methylation differences. Clustering analy-
sis was applied to visualize the differential DNA methylation patterns 
between groups. Further details are given in Supplementary Material, 
available at Carcinogenesis Online.
Gene enrichment analysis
A global gene enrichment analysis (GEA) was applied to the statistically 
significant differentially methylated CpG sites (referred to as differential 
CpGs) between CFs and TAFs using R software. All possible genes related 
to each differential CpG were individually considered, sharing the same 
β-value. The resulting list of genes was first filtered to avoid redundances, 
assigning the maximum β-value observed among repeated genes; sec-
ondly, by selecting genes with absolute │Δβ│ = │βTAF − βCF│> 0.2. The pack-
age clusterProfiler (v2.0.0) (19) was used to compute GEA over the final list 
of genes. Queried biological pathways were from KEGG (20) and Reactome 
(21) databases, accessed through the packages KEGG.db and reactome.db, 
respectively. In both cases, a P value for each gene was calculated based 
on a hypergeometric distribution test (5% FDR). The package topGO was 
used to conduct GEA for the Gene Ontology (GO) Biological Processes 
database (22). Results were prioritized based on P values obtained with 
Fisher’s exact test statistic and weight method (23). GEA corresponding 
to the TGF-β pathway was conducted with the KEGG TGF-β signalling 
(hsa04350) through the package KEGGgraph v1.24.0 (24). Genes annotated 
in this pathway were matched to the former list of genes with │Δβ│>0.2. 
The same procedure was applied to the TGF-β receptor signaling path-
way from Netpath database (NetPath_7) (25). Complete package references 
and further details are provided in Supplementary Material, available at 
Carcinogenesis Online.
Pyrosequencing
Bisulfite-treated DNA was used as a template for PCR. The primers for PCR 
amplification and sequencing were designed with PyroMark assay design 
software version 2.0.01.15. Primer sequences (Supplementary Material, 
available at Carcinogenesis Online) were designed, when possible, to hybrid-
ize with CpG-free sites to ensure methylation-independent amplification. 
Pyrosequencing analyses were performed as described previously (26).
qRT-PCR
For transcriptional analysis of selected genes that exhibited differential 
DNA methylation between CFs and TAFs, cells were cultured using the 
same protocol than for DNA methylation profiling. Total RNA was iso-
lated using the RNeasy Mini kit (QIAGEN) and reverse-transcribed into 
cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). qRT-PCR reactions were performed in triplicates on a 7900HT 
Fast Real-Time PCR system (Applied Biosystems) using 20 ng cDNA, SYBR 
Green PCR Master Mix (Applied Biosystems) and specific primers for 
SMAD3, EDARADD, CHI3L1 and ACTB (used as housekeeping gene). Primer 
pairs were designed with PerlPrimer v1.1.14 software and validated by gel 
electrophoresis to amplify specific single products. For ECM expression 
analysis, RNA extraction and reverse transcription was conducted using 
the same procedure. Real-time PCR reactions were performed on 50 ng 
of each cDNA sample using TaqMan Gene Expression Master Mix and 
TaqMan gene-specific primer pairs and probes for COL1A1, LOX, SPARC, 
TNC and POLR2A (used as a housekeeping gene). Primers and probes for 
detection of EDA-FN were customary designed based on the sequences 
reported elsewhere (27). Relative gene expression with respect to a house-
keeping gene was assessed as 2−ΔCt as described previously (28). Details 
of primers and probes are given in Supplementary Material, available at 
Carcinogenesis Online.
Immunofluorescence
Fibroblast cultures were fixed with 4% paraformaldehyde, permeabilized 
and blocked with 0.2% Triton X-100, 1% bovine serum albumin (Sigma) 
and 6% FBS (Gibco), firstly incubated with an anti-α-SMA mouse antibody 
(clone 1A4, Sigma), and secondly with a Cy3 goat anti-mouse IgG second-
ary antibody (Jackson). Nuclei were counterstained with Hoechst 33342 
(Molecular Probes). Fluorescence images were acquired with an Eclipse 
TE2000 microscope (Nikon) at nine randomized locations with an EM-CCD 
C9100a camera (Hamamatsu) using Metamorph software (Molecular 
Devices) and a ×20 objective. Each image was background corrected and 
its total intensity (I) and cell number (N) was measured with Image J. All 
I versus N data for each culture condition were least-squares fitted to a 
linear function with MATLAB (Mathworks) to assess the α-SMA intensity 
per cell as the fitted slope.
Flow cytometry
The percentages of cells positive for the cell surface markers CD34 and 
CD45 were assessed by flow cytometry. For this purpose, primary fibro-
blasts (CFs and paired TAFs) were cultured in 10% FBS culture medium for 
24 h before the experiment, and detached with trypsin-EDTA (Sigma) for 
1 min at 37°C. Fresh 10% FBS medium was added to quench the trypsin 
and cells were pelleted by centrifugation and kept with 10% FBS in sus-
pension at room temperature for 2 h to enable the restoration of cell 
surface epitopes. Suspended cells were washed with PBS, incubated for 
30 min with 2  µg/ml APC-conjugated antibodies against either CD34 or 
CD45 (Biolegend) in blocking solution (5% FBS in PBS) on ice in dark condi-
tions. Cells were washed with 0.5% bovine serum albumin in PBS solution, 
resuspended with PBS and analyzed as single cells with a flow cytometer 
(Gallios, Beckman Coulter) using FlowJo 10.0 software software. Additional 
details are provided in Supplementary Material, available at Carcinogenesis 
Online.
Traction force microscopy
Maps of traction forces were assessed in single fibroblasts using con-
strained Fourier transform traction microscopy as described elsewhere 
(29,30). Briefly, collagen-coated polyacrylamide gels with embedded 
fluorescent nanobeads were prepared by mixing 7.5% acrylamide and 
0.06% bisacrylamide to achieve E ~ 6 kPa. Cells were cultured in SFM in 
the absence or presence of 2.5 ng/ml TGF-β1 for 5 days. A map of gel dis-
placement and the corresponding traction force map were computed as 
described previously (29,30). The average traction force per unit area was 
computed and averaged over ~10 cells per condition.
Re-analysis of public cancer DNA methylation and 
expression datasets
Available Infinium 450K DNA methylation experimental data of clinical 
NSCLC specimens with detailed clinical annotation (13) (GSE39279) were 
correlated with survival parameters. For each selected gene, we collected 
its differentially methylated CpGs and established a β-value threshold to 
split the data in two groups: high (β > 0.33) and low (β < 0.33). The cor-
responding Kaplan–Meier survival curves were obtained with R soft-
ware, and their statistical significance was assessed with the log-rank 
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test. A similar procedure was applied on gene expression data and sur-
vival parameters from stages I to II lung NSCLC available elsewhere (31) 
(GSE31210).
Statistical analysis
Two-group comparisons of non-methylation array data were performed 
with the Student’s t-test unless otherwise indicated. Statistical signifi-
cance was assumed at P < 0.05.
Results
DNA methylation profiling reveals a global 
hypomethylation in TAFs
A major hallmark of lung TAFs in vivo is the expression of 
alpha-smooth muscle actin (α-SMA) (6), which is indicative of 
an activated/myofibroblast-like phenotype (32). Primary TAFs 
recapitulate this hallmark in culture, according to their larger 
α-SMA expression compared to CFs in all patients examined 
(Figure  1A). To shed light on the epigenetic alterations under-
lying the persistent TAF activation in culture, we conducted a 
genome-wide DNA methylation profiling on TAFs and paired 
CFs from 12 randomly selected patients from our cohort using 
the Infinium 450K Methylation Array. Comparing β-values in CFs 
and TAFs identified 18 520 statistically significant differentially 
methylated CpG sites outside X chromosome (Δβ ≠ 0; P < 0.002, 
5% FDR) (Supplementary Table  2, available at Carcinogenesis 
Online). Differentially methylated sites in CFs and TAFs were 
preferentially located in non-promoter (76%) rather than gene 
promoter (24%) sequences. In contrast, no statistically signifi-
cant differentially methylated sites were found within TAFs 
from different histologic subtypes. Therefore, only two groups 
(CFs and TAFs) were considered in further analyses.
Among the list of 18 520 differential CpGs in CFs and TAFs, 
1452 exhibited marked DNA methylation differences (taken 
as absolute Δβ ≥ 0.2 henceforth), which corresponded to 750 
distinct genes. An unsupervised clustering analysis of the lat-
ter 1452 probes shown in Figure 1B revealed a clear sorting of 
CFs and TAFs, with a global DNA hypomethylation concomi-
tantly with DNA hypermethylation of a smaller set of genomic 
regions in TAFs compared to CFs. To analyze quantitatively the 
global loss of DNA methylation, we assessed the distribution 
of β-values within the 1452 probes with marked differential 
methylation. A clear shift towards lower β-values was observed 
in TAFs compared to CFs (Wilcoxon test, P < 0.001), with a 19.4% 
reduction of median DNA methylation values in TAFs (dashed 
vertical lines in Figure 1C).
Global hypomethylation in TAFs is partially elicited 
by TGF-β1 but not matrix stiffening
To examine the relationship between an activated phenotype and 
global loss of DNA methylation, we analyzed the impact of two 
fibroblast activation signals frequently observed in the desmo-
plastic tumor stroma (9): TGF-β1 and ECM stiffening. For this pur-
pose, we first cultured CFs from two randomly selected patients 
(P5 and P28) in stiff substrata for 5 days in the presence or absence 
of TGF-β1 and analyzed their corresponding DNA methylation 
profiles with the 450K Methylation Array. TGF-β1 increased α-
SMA expression in CFs (Figure 2A) and elicited a statistically sig-
nificant reduction on DNA methylation (2.2%, P < 0.01) (Figure 2B). 
However, the latter drop could not account for the 18.8% reduc-
tion of DNA methylation observed in TAFs from the same patients 
in stiff substrata in the absence of TGF-β1 (P < 0.001, Figure 2C), 
indicating that such 18.8% reduction is largely imputable to the 
transformation process. Moreover, we found that 14.3% of the CpG 
sites in CFs with the largest variability upon TGF-β1 treatment 
(Supplementary Table  3A and Supplementary Material, avail-
able at Carcinogenesis Online) overlapped the 1452 differentially 
methylated CpG sites in CFs and TAFs. Secondly, we cultured CFs 
on polyacrylamide gels engineered to exhibit either normal- (~1 
kPa) or tumor-like (~30 kPa) rigidities in the presence of TGF-β1 
(Figure 2D). Unlike Figure 2B, DNA methylation differences of CFs 
cultured in these conditions were very modest, and only showed 
0.7% reduction in the median β-value in cells cultured in the stiff-
est gels (non-statistically significant, Figure  2E). Likewise, only 
one of the differentially methylated CpG sites with the largest 
variability induced by matrix stiffening (Supplementary Table 3B 
and Supplementary Material, available at Carcinogenesis Online) 
overlapped with the 1452 differentially methylated CpG sites 
in CFs and TAFs. Altogether, these results indicate that TGF-β1 
stimulation of CFs in a stiff microenvironment contributes to the 
aberrant DNA methylation pattern observed in TAFs but does not 
fully recapitulate it, whereas matrix stiffening in a TGF-β1-rich 
microenvironment does not have any significant contribution.
Figure 1. Primary lung TAFs exhibit global DNA hypomethylation and focal gain of DNA methylation. (A) Representative fluorescence images illustrating α-SMA over-
expression in lung TAFs compared to paired CFs obtained with a ×20 objective (top). Scale bars here and thereafter, 30 μm. The bottom plot shows the quantification 
of fold α-SMA intensity per cell of fibroblasts from four randomized patients. (B) Unsupervised clustering of 1452 CpG sites with marked differential methylation in 
TAFs and CFs from 12 randomized patients of our cohort and (C) normalized distribution (relative density) of the corresponding β-values. Dashed vertical lines indicate 
median β-values. *P < 0.05; **P < 0.01; ***P < 0.001 (here and thereafter). 
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DNA methylation changes affect pathways 
associated with ECM/focal adhesions and  
the FCγ receptor
To gain insights on the functional consequences caused by the 
observed changes on DNA methylation, we conducted a path-
way enrichment analysis selecting those genes from our list 
with marked methylation differences using three complemen-
tary databases: KEGG, Reactome and GO Biological Processes. 
Figure  3A shows a plot with the overrepresented KEGG path-
ways (P  <  0.05, 5% FDR) (Supplementary Table  4A, available at 
Carcinogenesis Online). The corresponding enrichments obtained 
with Reactome and GO are shown in Supplementary Figures 
1–2 and Supplementary Tables 4B–E, available at Carcinogenesis 
Online. Among the statistically significant enriched pathways or 
processes, only two were coincidentally reported in all three data-
bases. Such pathways were closely related to the ECM/focal adhe-
sions and the FCγ receptor (FCγR). Enhanced ECM deposition and 
cell–ECM interactions have been described previously as myofi-
broblast hallmarks (4,9). In contrast, FCγRs have been associated 
with immune cells rather than myofibroblasts (33,34). A straight-
forward explanation for the FCγR pathway enrichment is that it 
reflects the presence of fibrocytes, since these are bone marrow-
derived cells that express FCγRs as well as leukocyte (CD45) and 
hematopoietic progenitor (CD34) markers, and can differentiate 
into fibroblasts/myofibroblasts in response to TGF-β (33,34). To test 
this possibility, we examined CD34 and CD45 expression in tumor 
histologic sections from our cohort (n = 20) upon the guidance of 
our pathologist (JR), and observed several CD34+ and CD45+ stro-
mal mesenchymal cells (Figure 3B and Supplementary Figure 3, 
available at Carcinogenesis Online). In addition, we assessed CD34+ 
and CD45+ fibroblasts in culture by flow cytometry. Although 
the percentages of CD34+ and CD45+ fibroblasts were collec-
tively modest, they were consistently larger in TAFs compared 
to paired CFs in 3 randomly selected patients (Figure 3C,D and 
Supplementary Figure 3, available at Carcinogenesis Online). These 
results strongly support that a fraction of primary lung TAFs may 
be fibrocytes or fibrocyte-like cells in origin.
DNA methylation alterations of genes and miRNAs 
involved in fibroblast activation
TGF-β signaling is essential for fibroblast activation, and its cor-
responding KEGG pathway was found overrepresented in TAFs 
(Figure  3A). To delimit the scope of altered TGF-β signaling in 
TAFs, we sought to identify those genes annotated to the TGF-β 
signaling pathway available in either KEGG or NetPath databases 
that appeared in our list of differentially methylated genes in 
TAFs with respect to CFs. Among the 274 genes annotated to the 
TGF-β pathway in both databases, a marked differential methyl-
ation was observed selectively in 24 genes (9%) (Supplementary 
Table  5, available at Carcinogenesis Online). Of note, only 8 of 
the latter 24 genes exhibited a marked differential DNA meth-
ylation in promoter regions, including 4 important transcription 
factors: SMAD3 and the runt domain-containing family RUNX1, 
RUNX2 and RUNX3. Among them, SMAD3 was hypermethylated 
whereas RUNX genes exhibited a loss of DNA methylation in 
TAFs. Thus, even though methylation changes were only found 
in a modest percentage of genes annotated to the TGF-β path-
way, these changes affected the critical component SMAD3.
Figure 2. Activating CFs with TGF-β1 partially mimics the genomic methylation changes in TAFs. (A) Effect of TGF-β1 on α-SMA fluorescence staining in CFs. (B) Effect of 
TGF-β1 on the DNA methylation distribution of the list of 1452 differential CpG sites in CFs from two randomly selected patients (P5 and P28). Dashed horizontal lines 
indicate the median of each distribution. (C) DNA methylation distribution of the list of 1452 differential CpG sites in CFs and paired TAFs from the same patients. (D) 
Outline of the culture assay based on polyacrylamide gels with normal- or tumor-like rigidities in the presence of TGF-β1. (E) Effect of culture conditions shown in (D) 
on the DNA methylation distribution of the list of 1452 differential CpG sites in CFs from the same patients.
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In addition to TGF-β signaling, there is evidence that fibro-
blast activation may be epigenetically regulated by a growing 
list of miRNAs (9,35). Among those described previously in the 
literature, none exhibited a robust differential methylation in 
promoter regions in our dataset. In contrast, we identified three 
miRNAs with a marked hypomethylation affecting different 
CpGs in promoter regions that have not been previously associ-
ated with fibroblast activation: miR-296, miR-298 and miR-1249.
Impact of aberrant DNA methylation in transcription
Aiming to examine the impact of DNA methylation alterations 
on gene transcription, we analyzed the differential gene expres-
sion of genes undergoing large DNA methylation changes at 
promoter sequences, which are sorted in Tables 1 and 2 accord-
ing to their number of differentially methylated CpG sites 
and maximum DNA methylation change (full list is given in 
Supplementary Table 6, available at Carcinogenesis Online). Close 
examination of the top genes in Tables 1 and 2 identified SMAD3 
and EDARADD among those with the most consistent DNA meth-
ylation changes in the lists of promoter hypermethylated and 
hypomethylated genes, respectively. To expand our candidate 
selection, we took advantage of the differential transcriptional 
profiling of lung TAFs and paired CFs obtained from a cohort of 
15 early stage NSCLC patients analyzed by Navab and coworkers 
(5). This study identified 46 differentially expressed genes in TAFs 
and CFs with an absolute fold change >2. Among them, 22 (48%) 
were coincidental with the probes differentially methylated in 
our dataset (Supplementary Table  7, available at Carcinogenesis 
Online), yet only CHI3L1 consistently exhibited a marked DNA 
methylation change (│Δβ│ > 0.2) in its promoter region. Based on 
these analyses, SMAD3, EDARADD and CHI3L1 were selected for 
subsequent validation by pyrosequencing. Our results confirmed 
the increased DNA methylation in SMAD3 promoter sequence 
Figure 3. Pathway-enrichment analysis reveals that a fraction of TAFs are fibrocyte or fibrocyte-like cells in origin. (A) Statistically significant overrepresented KEGG 
pathways within the 750 distinct genes corresponding to the list of 1452 CpG sites with marked differential methylation between TAFs and CFs. Pathway’s circle size is 
proportional to the number of annotated genes. Genes annotated to each pathway are color-coded according to their fold DNA methylation. None, one or two circles 
around each gene indicate that differential methylation was found within non-promoter, promoter, or both non-promoter and promoter regions, respectively. (B) Repre-
sentative images of tumor histologic sections of a randomly selected patient from our cohort stained for fibrocyte markers CD34 (left) and CD45 (right). Black arrows point 
to CD34+ and CD45+ (non-endothelial) spindle-shaped stromal mesenchymal cells. (C) Histograms of CD34+ (left) and CD45+ (right) cultured CFs and TAFs from the same 
patient as in (B) assessed by flow cytometry. (D) Fold (TAFs/CFs) percentages of CD34+ and CD45+ fibroblasts from three randomly selected patients assessed as in (C).
Table  1. Differential methylation in promoter sequences in lung 
TAFs. Hypermethylated genes with marked differential methylation 
(│Δβ │ > 0.2) in promoter sequences in lung TAFs in ≥ 2 CpG sites 
Gene symbol CpG sites Highest Δβ = βTAF − βCF
Hypermethylated SMAD3 4 0.236
SYNPO 3 0.211
GPR88 2 0.276
C7orf54 2 0.272
SND1 2 0.272
TMEM212 2 0.248
LOC404266 2 0.241
TTC39C 2 0.230
ZMIZ1 2 0.225
EYA4 2 0.220
M.Vizoso et al. | 1459
(P < 0.001). Likewise, DNA hypomethylation was validated in both 
EDARADD and CHI3L1 promoter sequences (P  <  0.001) in TAFs 
compared to paired CFs (Figure 4A). To determine the impact of 
these epigenetic changes on transcriptional activity, we assessed 
mRNA levels of the three selected genes by qRT-PCR (Figure 4B). 
SMAD3 levels were down-regulated in TAFs compared to paired 
CFs in all patients (P  <  0.05), in agreement with the transcrip-
tional repression associated with promoter DNA hypermeth-
ylation. Conversely, increased expression levels were observed 
in both EDARADD (P < 0.05) and CHI3L1 (P < 0.05) in TAFs with 
respect to paired CFs, in agreement with transcriptional reactiva-
tion upon loss of DNA methylation at the promoter.
Clinical value of selected genes
The clinical impact of the three validated genes was assessed in 
terms of prognosis. For this purpose, we first examined the DNA 
methylation status of the three genes on a previously published 
cohort of 204 tumor tissue samples from NSCLC patients (13). Of 
note, EDARADD promoter hypomethylation was associated with 
a shorter disease-associated survival (Log-rank test, P  <  0.01) 
in comparison with those patients exhibiting higher levels of 
promoter methylation (Figure 4C). In agreement with the worst 
prognosis conferred by EDARADD promoter DNA hypomethyla-
tion, high levels of EDARADD expression were consistently asso-
ciated with shorter survival (Log-rank test, P < 0.01) (Figure 4D) 
according to a publicly available gene expression database from a 
cohort of 226 NSCLC patients (31). Unlike EDARADD, no prognos-
tic information was observed in SMAD3 or CHI3L1 methylation 
status in the same data sets (Supplementary Figure 4, available 
at Carcinogenesis Online). To further validate the expression of 
EDARADD in clinical specimens, we examined its protein level 
in TAFs by immunohistochemistry in our cohort of 20 patients 
(Figure 4E and Supplementary Figure 5, available at Carcinogenesis 
Online). In tumor samples, EDARADD expression was hetero-
geneous and could be observed in both TAFs and cancer cells, 
whereas it was largely absent in parenchymal cells from unaf-
fected tissue. In agreement with our qRT-PCR data, quantitative 
image analyses revealed a higher percentage of stromal fibro-
blasts with strong EDARADD staining compared to unaffected 
lung parenchyma (used as control) (Figure 4F; P < 0.05).
SMAD3 hypermethylation in TAFs is associated 
with an aberrant response to TGF-β1 in terms of 
contractility and ECM expression
To get insights on the functional impact of the selective SMAD3 
epigenetic silencing in TAFs, we took advantage of a previous 
work on Smad3-null mice, which reported two skin fibroblast-
associated altered functions in vivo: (i) increased ECM deposi-
tion in response to exogenous TGF-β1; and (ii) enhanced wound 
healing rate possibly due to enhanced contractility upon skin 
injury (36). To assess whether the latter in vivo phenotype of 
skin fibroblasts could be extended to lung TAFs in culture, we 
first examined the expression of a panel of wound-related ECM 
genes (COL1A1, EDA-FN, LOX, SPARC and TNC) commonly associ-
ated with fibroblast activation (32) by qRT-PCR. For this purpose, 
TAFs and paired CFs from randomly selected patients were cul-
tured with TGF-β1 for 5  days. Fold expression data (TAFs/CFs) 
showed a marked (>>1-fold) overexpression of all ECM genes 
except TNC in most patients (Figure 5A). Secondly, we assessed 
fibroblast contractility by traction force microscopy. Mean trac-
tion forces increased in response to TGF-β1 in both TAFs and CFs 
(Figure 5B); however, such contractility increase was ~40% larger 
in average in TAFs than in CFs (Figure  5C). To our knowledge, 
these findings unveil for the first time an aberrant hyperrespon-
siveness of lung TAFs to TGF-β1 in terms of ECM expression and 
contractility.
Discussion
In the present study, we interrogated for the first time the DNA 
methylation landscape changes between CFs and paired TAFs 
from surgical patients with early stage NSCLC using the high-
resolution Infinium 450K DNA Methylation Array. We observed 
a global DNA hypomethylation and selective promoter DNA 
hypermethylation in TAFs compared to CFs. Therefore, the DNA 
methylation alterations in TAFs could be attributed to their 
neoplastic transformation, and included a ~19.4% reduction 
in the median DNA methylation levels compared to CFs. Such 
loss of DNA methylation is in quantitative agreement with that 
reported in TAFs from two gastric cancer patients (15), and in 
qualitative agreement with the global DNA hypomethylation 
reported in TAFs from breast cancer (8) and from a mouse pan-
creatic cancer model (37). Likewise, we confirmed and expanded 
the catalogue of DNA methylation alterations in TAFs (15). 
Collectively, these findings support that global DNA methylation 
loss concurrent with focal hypermethylation define a general 
Table 2. Hypomethylated genes with marked differential methyla-
tion (│Δβ │ > 0.2) in promoter sequences in lung TAFs in ≥ 2 CpG sites
Gene symbol CpG sites Highest Δβ = βTAF − βCF
Hypomethylated IVL 5 −0.261
RUNX1 4 −0.319
C22orf9 4 −0.298
MIR1249 4 −0.298
NTM 4 −0.245
CSGALNACT1 3 −0.314
IPO5 3 −0.303
EDARADD 3 −0.295
SLAMF8 3 −0.283
SLC22A18AS 3 −0.271
SLC22A18 3 −0.271
SMCP 3 −0.244
MIR298 3 −0.230
MIR296 3 −0.230
SCT 2 −0.351
PARP4 2 −0.316
EPS15 2 −0.297
WIPF1 2 −0.291
HRH1 2 −0.280
FAM49A 2 −0.277
CHRM5 2 −0.270
RUNX3 2 −0.263
TSPAN9 2 −0.262
CARD14 2 −0.259
S100A3 2 −0.258
GNASAS 2 −0.254
ZC3H12D 2 −0.254
PLEKHA5 2 −0.249
LEPR 2 −0.242
LEPROT 2 −0.242
CHRNA1 2 −0.231
ESRRG 2 −0.229
STRA6 2 −0.224
HTR1D 2 −0.221
GSTA3 2 −0.220
SH3BP4 2 −0.217
LCE1B 2 −0.207
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epigenetic hallmark of TAFs from solid tumors, and may under-
lie their ‘phenotypic memory’ in culture.
It is commonly assumed that lung TAFs are a heterogenous 
population with similar tumor-promoting effects regardless 
their histologic subtype of origin. However, some of us recently 
challenged this assumption by reporting phenotypic differences 
in TAFs from major histologic subtypes (6). In contrast, we did 
not find statistically significant diferentially methylated CpGs 
within subtypes. A  possible interpretation of these results is 
that a larger patient cohort may be required to unveil the fine 
subtype-specific DNA methylation alterations. Alternatively, it 
is conceivable that, in addition to DNA methylation, the ‘epige-
netic memory’ of the subtype-specific phenotypic differences in 
TAFs is supported by other epigenetic alterations.
The robust global DNA hypomethylation in TAFs raises the 
question of its underlying mechanism(s). A  potential straight-
forward molecular mechanism could be an altered DNA meth-
yltransferase activity. However, this mechanism is unlikely 
according to previous data (15). Alternatively, it is conceivable 
that chronic fibroblast activation and DNA hypomethylation are 
Figure 4. Validation of differential methylated promoters and the prognostic value of EDARADD in NSCLC with high stromal mesenchymal expression in-vivo. (A) DNA 
methylation of selected genes measured by pyrosequencing in TAFs and paired CFs from 12 patients. (B) Fold (TAFs/CFs) relative mRNA expression of selected genes 
in five randomized patients by qRT-PCR. Horizontal dashed lines here and thereafter are added as a reference. (C) Kaplan–Meier survival curve using publicly available 
data of a cohort of 204 NSCLC patients (161 ADC, 43 SCC) sorted by their EDARADD DNA methylation status assessed in primary tumoral DNA (13). (D) Kaplan–Meier 
survival curve using publicly available data of a cohort of 226 NSCLC patients (226 ADC) sorted by their EDARADD expression assessed in primary tumors (31). (E) Rep-
resentative images of histologic sections from our cohort stained for EDARADD obtained from unaffected lung parenchyma (control, left) or tumor (right). Black arrows 
within inserts point to EDARADD+ spindle-shaped mesenchymal cells. (F) Scoring of EDARADD protein expression in (non-endothelial) spindle-shaped stromal cells in 
our cohort of 20 NSCLC patients (10 ADC, 10 SCC).
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mechanistically interconnected (38–40). To begin to explore this 
possibility in primary lung TAFs, we examined the genomic meth-
ylation effects of two potent fibroblast activator cues: TGF-β1 and 
matrix stiffening (6,9,41). Interestingly, whereas TGF-β1 treatment 
recapitulated some of the epigenetic changes associated with 
tumorigenesis, matrix stiffening failed to elicit similar alterations. 
These results are in agreement with a previous study describing 
that TGF-β1 might be associated with global DNA hypomethyla-
tion in gastric cancer (42). Importantly, our data suggest that TGF-
β1 may be necessary but not sufficient to induce the aberrant 
genomic methylation in TAFs, suggesting that factors other than 
TGF-β1 reshape their epigenome. In support of the latter interpre-
tation, it has been suggested that chronic inflammation, aberrant 
differentiation of local or recruited circulating progenitor cells 
like fibrocytes, or abnormal paracrine signaling by cancer cells 
may also underlie the global demethylation of TAFs (3).
The elucidation of the pathologic consequences of global 
hypomethylation remains a matter of intense research. In 
cancer cells, global loss of DNA methylation has been associ-
ated with genomic alterations including chromosome instabil-
ity, activation of transposable elements and loss of genomic 
imprinting, which may contribute to cancer development 
through either increased genomic instability and/or aberrant 
gene expression (43,44). Currently available data do not sup-
port the former events in TAFs (15). In contrast, two lines of 
evidence support that the aberrant TAF methylome may have 
a global impact on gene expression. First, within a list of 46 
genes with marked differential expression between lung TAFs 
and CFs reported by Navab and coworkers (5), 22 exhibited also 
differential DNA methylation in our study (Supplementary 
Table  7, available at Carcinogenesis Online). Such large overlap 
is in marked contrast with the single differentially methylated 
gene from the 46 gene list that was reported in the same study, 
based on DNA methylation profiling obtained with the Illumina 
27K BeadChip Methylation Array (5); however, this discrepancy 
can be easily accounted for by the larger genomic coverage of 
the 450K Methylation Array used in our study. Second, a wide-
spread impact of aberrant DNA methylation in gene expression 
is expected by the identification of three miRNAs with marked 
DNA methylation changes in promoter regions, according to the 
growing list of their potential transcriptional targets.
In addition to a global impact on gene expression, DNA meth-
ylation changes had a selective impact in the promoter regions of 
important transcription factors downstream of TGF-β signaling: 
SMAD3 and the RUNX family of developmental factors. The lat-
ter family of factors is frequently deregulated in human cancers, 
where they may function as either oncogenes or tumor suppres-
sors according to their context. Likewise, RUNX proteins are criti-
cal regulators of TGF-β signaling in a context-dependent fashion 
(45). However, the tumor promoting functions of RUNX proteins in 
TAFs are currently unknown, and overall their roles in lung can-
cer remain poorly understood. In contrast, low SMAD3 expression 
is frequently observed in the stroma of lung tumors of current 
smokers (46), in agreement with its epigenetic silencing observed 
in this study. In fibroblasts, SMAD3 is considered a critical tran-
scription factor underlying TGF-β-induced α-SMA expression in 
lung and other organs (47,48). Yet, lung TAFs overexpressed α-
SMA compared to CFs, indicating that α-SMA expression is largely 
SMAD3-independent in TAFs, and revealing that TAFs may have 
an aberrant activated phenotype. In support of this interpreta-
tion, lung TAFs exhibited enhanced contractility and expression 
of wound-associated ECM genes compared to CFs, in qualitative 
Figure 5. SMAD3 epigenetic silencing in TAFs correlates with enhanced response to TGF-β1, ECM expression and contractility. (A) Fold (TAFs/CFs) relative mRNA expres-
sion of a panel of wound-related ECM genes in response to TGF-β1 in four randomized patients. (B) Illustrative traction maps of a single CF and paired TAF from the 
same patient under basal conditions or TGF-β1 stimulation. (C) Fold (TAFs/CFs) average traction force in four randomized patients. All data are mean ± SE.
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agreement with previous observations in skin fibroblasts in 
Smad3-null mice (36). These novel findings reveal that TAFs are 
hyperresponsive to exogenous TGF-β1, and strongly suggest that 
such hyperresponsiveness is intimately associated with the epi-
genetic silencing of SMAD3. Based on these observations, it is 
tempting to speculate that TGF-β1 hyperresponsiveness may be a 
major contributor to the formation and maintenance of the des-
moplastic stroma in NSCLC (6).
Pathway enrichment analysis of DNA methylation differences 
pointed at pathways and processes associated with ECM/focal 
adhesions and FCγR. The former enrichment was expected, since 
ECM pathways are directly associated with the myofibroblast 
phenotype. In agreement with this analysis, enrichment in the 
KEGG focal adhesion pathway was previously found from differ-
ential expression data between lung TAFs and CFs elsewhere (5). 
Unexpectedly, our analysis identified also an enrichment in path-
ways related to the FCγR, which has been associated with immune 
cells rather than myofibroblasts, for its main known function is to 
provide antigen-presenting activity (34). Nonetheless there is evi-
dence that bone marrow-derived fibrocytes do express FCγRs and 
can differentiate into fibroblasts/myofibroblasts (33,34), thereby 
raising the intriguing possibility that lung TAFs are enriched in 
differentiated fibrocytes. In support of this possibility, we found 
stromal cells in histologic sections with spindle-shaped nuclei 
and positivity for the hematopoietic proteins CD34 and CD45, 
which are well-defined fibrocyte markers. In agreement with 
these observations, the percentages of CD34+ and CD45+ fibro-
blasts in culture were more than ~2.5-fold larger in TAFs than 
CFs. Moreover, it is possible that the actual fibrocyte percent-
ages were underestimated, since fibrocytes that differentiate into 
fibroblasts/myofibroblasts frequently down-regulate CD34 and/
or CD45 (33,34). On the other hand, fibrocyte-like stromal cells 
have been documented in a growing list of human and murine 
tumors as well as in chronic inflammatory lung diseases (34,49). 
Therefore, these observations strongly support that a non-mar-
ginal percentage of lung TAFs derive from fibrocytes or fibrocyte-
like cells in addition to resident fibroblasts.
More than a dozen hypermethylated genes have been pre-
viously identified as biomarker candidates in patients with 
NSCLC (10,13). Among them, only PCDHGB6 was also found 
consistently hypermethylated in TAFs, although mostly within 
non-promoter regions, indicating that most of the former 
hypermethylation events are restricted to either cancer cells or 
stromal cells other than fibroblasts. On the other hand, among 
the validated genes that exhibited a marked differential meth-
ylation in promoter regions in lung TAFs, only EDARADD was 
associated with a worse progression-free survival in NSCLC 
patients when analyzing public databases of DNA methylation 
and gene expression. EDARADD is a NF-kappa-B related devel-
opmental gene (50) that was found epigenetically upregulated 
in TAFs in culture and in histologic sections, thereby emerging 
as a potential stromal biomarker. It also appeared upregulated 
in cancer cells compared to parenchymal cells, indicating that 
future studies are warranted to elucidate the tumorigenic roles 
of EDARADD expression in TAFs and cancer cells. Moreover, 
since no specific survival data of NSCLC patients concomi-
tant with DNA methylation in TAFs are available, it is conceiv-
able that additional differentially methylated genes other than 
EDARADD may bear prognostic value in the stroma.
Conclusions
There is an increasing interest in understanding the molecular 
alterations of TAFs, since they are the major cell type within the 
tumor-supporting stroma. Our study uncovered unprecedented epi-
genetic alterations in TAFs from NSCLC patients, including a global 
impact on gene expression and a selective impact on SMAD3 and 
other key transcription factors of the TGF-β pathway. Remarkably, 
these alterations were associated with a hyperresponse to exog-
enous TGF-β, which may account for the sustained desmoplastic 
stroma in vivo. Our analysis revealed also that a fraction of TAFs 
may be recruited from bone-marrow fibrocytes. In addition, we 
identified EDARADD as a stromal biomarker in terms of progno-
sis. Altogether, our findings provide novel molecular and cellular 
insights underlying the tumor-promoting phenotype of lung TAFs.
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